Can Status Epilepticus Sometimes Just Be a Long Seizure?

Unprovoked Status Epilepticus: The Prognosis for Otherwise Normal Children With Focal Epilepsy.


OBJECTIVE: To document the effect of unprovoked status epilepticus (SE) on the prognosis for otherwise normal children with focal epilepsy. METHODS: From the Nova Scotia Childhood Epilepsy Study (population based), we identified patients with focal epilepsy, normal intelligence, and neurologic examination and follow-up ≥ 10 years. We compared those with and without unprovoked SE. RESULTS: One hundred eighty-eight cases had a mean follow-up of 27 ± 5 years with no deaths from SE. Thirty-nine (20%) had SE, 19 of whom experienced their first seizure. The number of episodes of SE was 1 in 27 patients (69%) and 2 to 10 in 12 patients. At onset, 9 of 39 (23%) SE patients and 35 of 149 (23%) no-SE patients had specific learning disorders. At follow-up, 11 (28%) SE and 49 (33%) no-SE patients had learning disorders (P = not statistically different [ns]). Grades repeated, high school graduation, and advanced education did not differ. The number of antiepileptic drug (AED) used throughout the clinical course was the same: 22/39 (56%). SE patients used ≤ 2 AEDs versus 99 of 149 (64%) no-SE patients (P = .2). The distribution of patients using 3 to 11 AEDs was similar. The remission rate (seizure-free without AEDs at the end of follow-up) for SE patients was 24 of 39 (61%) versus 99 of 149 (66%) in no-SE (P = .5). Intractable epilepsy occurred in 15% SE and 11% of no-SE cases. CONCLUSIONS: SE often recurs but apparently has little influence on long-term intellectual and seizure outcome in normally intelligent children with focal epilepsy.

Commentary

Status epilepticus (SE) is a grave, life-threatening neurological emergency requiring rapid administration of definitive therapy to avoid irreversible brain injury (1), but it seems paradoxical that many children who experience it do surprisingly well. For instance, children who experience SE are no more likely to go on to develop chronic epilepsy than those who experience an ordinary, self-limited first seizure (2). Although prolonged seizures may be associated with subsequent development of hippocampal sclerosis (3), and a history of SE predicts a lower chance of seizure freedom after temporal lobectomy (4), nonetheless, children with SE and epilepsy were found to have only a modestly lower chance of achieving seizure remission than others with epilepsy in one prospective population-based study (5). While it is not surprising that individual patients experience cognitive deterioration after SE (6), this has not been proven for larger samples of patients. How often does SE, a potentially malignant phenomenon, have an apparently benign outcome?

This question is addressed by this study from the Camfields using the Nova Scotia Childhood Epilepsy population-based cohort. That province has a central EEG reading facility. Based on the assumption that children will receive an EEG for new onset of an unexplained seizure, these EEG records were used to identify all children with newly diagnosed epilepsy between 1977 and 1985. Contact had been maintained with these patients and their families, most recently in 2009–2011, to collect the information for analysis. This study looked at children with focal epilepsy (two or more unprovoked seizures) who had convulsive SE (> 30 minutes of unconsciousness with continuous or repeated seizures) at any time in their lives. In addition to requiring adequate follow-up, the study criteria required normal intelligence (IQ > 70) and no neurological deficits interfering with daily activities. Because of the era of diagnosis, MRI data was not included, but CT was available in 86%; approximately 60% of patients had no identifiable cause for epilepsy. The selection conditions, therefore, must eliminate some cases of remote symptomatic epilepsy, a subgroup with a higher risk of SE (5). It would not be surprising if patients with baseline cognitive impairment and other neurological disability would have different SE outcomes than those of neurologically normal patients in the current study.

This study looked at the consequences of SE, particularly evidence for brain injury or worsening of subsequent seizure control. The measure of brain injury addressed was cognitive function. Although many of these patients had follow-up neuropsychological testing, this information was not analyzed other than to note the presence of a learning disorder because this testing was not standardized or complete. However, it can be argued that neuropsychological testing is merely a surrogate for the ability to perform and succeed in life activities;
in this regard, SE and non-SE patients were no different, with equal educational achievements and earned income. Since all SE was convulsive, it is not surprising that generalized tonic–clonic seizures were more common in the SE patients, in all other respects, however, the course of subsequent epilepsy was similar in the two groups. This similarity included the percentage of focal seizures with altered consciousness, antiepileptic drug regimens, and average longest seizure-free period. Most importantly, the chance of achieving a sustained seizure-free remission off antiepileptic drugs at the end of the study was the same for SE and non-SE patients. So, unprovoked SE did not lead to cognitive deterioration or an increased chance of medically refractory epilepsy in this patient cohort.

Other studies provide additional perspectives. The occurrence of one episode of SE increases the risk of subsequent occurrences (7), and 31% of patients in the current Canadian study had multiple SE events. SE is more likely in remote symptomatic epilepsy, in focal epilepsy, and with epilepsy onset earlier in life (5, 7). The most relevant prior investigation, however, comes from another prospective population-based study, done in Finland (5): This was a group of 150 patients with childhood-onset epilepsy followed for more than 3 decades, of whom 27% had one or more SE episodes. Overall, SE did not affect long-term prognosis. It was most common at epilepsy onset and did not alter mortality rates. Even combining all patients, including those with neurological and cognitive deficits, there was only a modest decrease in the probability of attaining seizure remission. In subjects with no other neurological handicap, social and educational outcomes were similar in those with and without SE. Therefore, this Finnish and the current Canadian studies demonstrate a similarly favorable outcome for neurologically normal patients with SE in childhood-onset epilepsy.

This work shows that neurologically normal patients with childhood-onset epilepsy and SE have prognoses for life function and seizure control the same as those of similar patients without SE. In this situation SE can be regarded as “just a long seizure.” It cannot be assumed that this holds for other patient subgroups—such as those with acute provoked SE, with SE in the setting of baseline cognitive and neurological deficits, or with generalized or adult-onset epilepsies. It also does not mean that SE is not a dangerous event (8). These favorable outcomes reflect the timely interventions delivered by the excellent healthcare system of a Canadian province, and modern SE treatment with benzodiazepines and parenteral antiepileptic drugs (9). The results do mean that neurologically normal patients with childhood-onset epilepsy, and their families, can be counseled that the occurrence of unprovoked, well-treated SE usually does not change the prognosis.

by John W. Miller, MD, PhD

References
Instructions
The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

1. Identifying information.
   Enter your full name. If you are NOT the main contributing author, please check the box “no” and enter the name of the main contributing author in the space that appears. Provide the requested manuscript information.

2. The work under consideration for publication.
   This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking “No” means that you did the work without receiving any financial support from any third party – that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check “Yes”. Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

3. Relevant financial activities outside the submitted work.
   This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. For example, if your article is about testing an epidermal growth factor receptor (DGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

   Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work’s sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

   For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Other relationships
   Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.
Section #1 Identifying Information

1. Today’s Date: 7/25/12

2. First Name John Last Name Miller Degree MD, PhD

3. Are you the Main Assigned Author? ☑ Yes ☐ No

If no, enter your name as co-author:

4. Manuscript/Article Title: Can Status Epilepticus Sometimes Just Be a Long Seizure?

5. Journal Issue you are submitting for: 13.3

Section #2 The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

<table>
<thead>
<tr>
<th>Type</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comments**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Grant</td>
<td>☑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Consulting fee or honorarium</td>
<td>☑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Support for travel to meetings for the study or other purposes</td>
<td>☑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Fees for participating in review activities such as data monitoring boards, statistical analysis, end point committees, and the like</td>
<td>☑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Payment for writing or reviewing the manuscript</td>
<td>☑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Provision of writing assistance, medicines, equipment, or administrative support.</td>
<td>☑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Other</td>
<td>☑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts on this study.

** Use this section to provide any needed explanation.
### Section #3 Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the “Add” box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

<table>
<thead>
<tr>
<th>Type of relationship (in alphabetical order)</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comments**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Board membership</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Consultancy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Employment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Expert testimony</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Grants/grants pending</td>
<td></td>
<td></td>
<td>Yes</td>
<td>NIH, CDC, Sunovian, UCB, Esai, Pfizer</td>
<td>ROSE study, Project Uplift, Investigational antiepileptic medication trials</td>
</tr>
<tr>
<td>6. Payment for lectures including service on speakers bureaus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Payment for manuscript preparation.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Patents (planned, pending or issued)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. Royalties</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Payment for development of presentations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. Stock/stock options</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. Travel/accommodations/meeting expenses unrelated to activities listed.**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13. Other (err on the side of full disclosure)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts.
** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

### Section #4 Other relationships

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- No other relationships/conditions/circumstances that present a potential conflict of interest.
- Yes, the following relationships/conditions/circumstances are present:

John W. Miller
Thank you for your assistance.

Epilepsy Currents Editorial Board